Pluri Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yaacov Yanay
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building No. 5 Haifa Israel 3508409
- IPO Date
- Jun 30, 2003
- CIK
- 0001158780
- Website
- pluri-biotech.com
- Similar Companies
- Business
- Pluri Inc. (Nasdaq: PLUR; TASE: PLUR), a biotechnology company headquartered in Haifa, Israel, and founded in 2001, develops and manufactures cell-based products, therapeutics, and technologies leveraging its proprietary 3D cell expansion platform for regenerative medicine, immunotherapy, food technology, agtech, and related industries. The company's core offerings include placenta-derived cell therapy candidates such as PLX-PAD, comprising maternal placental mesenchymal stromal cells for treating acute muscle injuries post-hip fracture, acute respiratory distress syndrome, peripheral artery disease, intermittent claudication, critical limb ischemia, and pre-eclampsia; PLX-R18, consisting of fetal placenta-derived cells for addressing hematopoietic complications in acute radiation syndrome and cell transplantation; an allogeneic mucosal-associated invariant T (MAIT) cell immunotherapy platform targeting solid tumors; customized cell-based products supplied to pharmaceutical and research clients via its Contract Development and Manufacturing Organization (CDMO) division; cultivated meat, fish, seafood, and plant-based foods through subsidiaries like Ever After Foods and PluriFood; cell-based coffee via Coffeesai; cell-based chocolate through a majority stake acquisition in Kokomodo; and agtech solutions via PluriAgtech including alternative farming methods and partnerships for cocoa and coffee production. Pluri operates a GMP-compliant facility enabling scalable, consistent production of high-quality cells and proteins, supported by over 140 granted patents across 52 countries, and serves global markets in healthcare, food, and agriculture with approximately 118 employees. Recent developments include a $10 million funding round led by strategic healthcare investors in 2025; a $6.5 million investment from Alejandro Weinstein tied to the Kokomodo acquisition for cell-based chocolate; new international collaborations in foodtech and agtech through Ever After Foods, Kokomodo, and Coffeesai announced in November 2025; a fourfold revenue increase to $938,000 in the first nine months of fiscal 2025 from CDMO launches and agtech proof-of-concept deals; granted U.S. and Israeli patents for 3D immune cell expansion; strategic partnerships with Tnuva Group for cell-based foods, Bar-Ilan University, Hemafund for nuclear response, and pursuits in cocoa and coffee industries; and new business verticals in PluriAgtech, PluriCDMO, PluriHealth, and PluriFood.
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
Pluri Inc. (NASDAQ:PLUR) Sees Large Increase in Short Interest
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved
Pluri (NASDAQ:PLUR) Stock Price Down 12.7% – Here’s Why
Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Plurilock Corporate Update for Shareholders
Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method